Scholarlink

Background <p>Cervical cancer remains a major health problem, and HPV-independent subtypes such as gastric-type adenocarcinoma carry dismal outcomes. Although immune checkpoint inhibitors (ICIs) have improved survival in large trials, their real-world effectiveness including HPV-independent tumors is not well established.</p> Methods <p>We conducted a retrospective multicenter study of two surrogate cohorts representing refractory cervical cancer: patients treated with bevacizumab (Bev-cohort, <i>n</i> = 65) and those undergoing comprehensive genomic profiling (CGP-cohort, <i>n</i> = 42). Early ICI administration was evaluated using landmark analysis (Bev: 180&#xa0;days; CGP: 6&#xa0;months), with differences in restricted mean survival time (ΔRMST) as the primary endpoint. Multivariable Cox models adjusting for stage, histology, and treatment interval were performed as secondary analyses. Exploratory analyses assessed HPV and molecular status for associations with ICI response.</p> Results <p>In the Bev-cohort, 14 ICI-treated patients achieved significantly longer survival than 48 non-ICI patients (ΔRMST + 19.4&#xa0;days at 180&#xa0;days; + 56.2&#xa0;days at 360&#xa0;days). Multivariable Cox confirmed ICI as an independent predictor of survival (HR 0.15, 95%CI 0.01–0.69). In the CGP-cohort, 11 ICI-treated patients also experienced superior survival compared with 20 non-ICI patients (ΔRMST + 1.05&#xa0;months at 6&#xa0;months; + 2.33&#xa0;months at 12&#xa0;months). Among 36 ICI-treated cases overall, efficacy was not clearly associated with PD-L1 or tumor mutation burden status. Importantly, HPV-independent tumors, including gastric-type adenocarcinoma, demonstrated progression-free survival comparable to HPV-associated tumors.</p> Conclusion <p>ICIs improved survival in advanced refractory cervical cancer across two real-world cohorts. HPVI may respond favorably, but further studies are needed.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-world multicenter study of immune checkpoint inhibitors in advanced cervical cancer across HPV-associated and HPV-independent subtypes

  • 期刊论文

  • 发表日期：

    2025年11月26日

查看全文
  • Kazuhiro Ko,
  • Mayu Fukuda,
  • Koji Yamanoi,
  • Nobutaka Hayashi,
  • Hisateru Yasui,
  • Takuma Hayashi,
  • Yoshihiro Yakushijin,
  • Takehiko Tsumura,
  • Atsushi Shirakawa,
  • Chiho Nakashima,
  • Yoshinori Imamura,
  • Chikako Yamauchi,
  • Toshio Shimizu,
  • Takahito Ashihara,
  • Nobuhiro Shibata,
  • Takeshi Kotake,
  • Aya Toyofuku,
  • Taito Miyamoto,
  • Rin Mizuno,
  • Mana Taki,
  • Ryusuke Murakami,
  • Satoshi Morita,
  • Manabu Muto,
  • Masaki Mandai

摘要

Background

Cervical cancer remains a major health problem, and HPV-independent subtypes such as gastric-type adenocarcinoma carry dismal outcomes. Although immune checkpoint inhibitors (ICIs) have improved survival in large trials, their real-world effectiveness including HPV-independent tumors is not well established.

Methods

We conducted a retrospective multicenter study of two surrogate cohorts representing refractory cervical cancer: patients treated with bevacizumab (Bev-cohort, n = 65) and those undergoing comprehensive genomic profiling (CGP-cohort, n = 42). Early ICI administration was evaluated using landmark analysis (Bev: 180 days; CGP: 6 months), with differences in restricted mean survival time (ΔRMST) as the primary endpoint. Multivariable Cox models adjusting for stage, histology, and treatment interval were performed as secondary analyses. Exploratory analyses assessed HPV and molecular status for associations with ICI response.

Results

In the Bev-cohort, 14 ICI-treated patients achieved significantly longer survival than 48 non-ICI patients (ΔRMST + 19.4 days at 180 days; + 56.2 days at 360 days). Multivariable Cox confirmed ICI as an independent predictor of survival (HR 0.15, 95%CI 0.01–0.69). In the CGP-cohort, 11 ICI-treated patients also experienced superior survival compared with 20 non-ICI patients (ΔRMST + 1.05 months at 6 months; + 2.33 months at 12 months). Among 36 ICI-treated cases overall, efficacy was not clearly associated with PD-L1 or tumor mutation burden status. Importantly, HPV-independent tumors, including gastric-type adenocarcinoma, demonstrated progression-free survival comparable to HPV-associated tumors.

Conclusion

ICIs improved survival in advanced refractory cervical cancer across two real-world cohorts. HPVI may respond favorably, but further studies are needed.